Supplementary Table 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Authors:
- Arielle ElkriefAEArielle Elkrief
- Alex MakhninAMAlex Makhnin
- Khadeja A. MosesKMKhadeja A. Moses
- Linda S. AhnLALinda S. Ahn
- Isabel R. PreeshagulIPIsabel R. Preeshagul
- Afsheen N. IqbalAIAfsheen N. Iqbal
- Sara A. HayesSHSara A. Hayes
- Andrew J. PlodkowskiAPAndrew J. Plodkowski
- Paul K. PaikPPPaul K. Paik
- Marc LadanyiMLMarc Ladanyi
- Mark G. KrisMKMark G. Kris
- Gregory J. RielyGRGregory J. Riely
Open Access
- 25 November 2025
- other
- Published by American Association for Cancer Research (AACR)